JP2021523140A5 - - Google Patents

Info

Publication number
JP2021523140A5
JP2021523140A5 JP2020562602A JP2020562602A JP2021523140A5 JP 2021523140 A5 JP2021523140 A5 JP 2021523140A5 JP 2020562602 A JP2020562602 A JP 2020562602A JP 2020562602 A JP2020562602 A JP 2020562602A JP 2021523140 A5 JP2021523140 A5 JP 2021523140A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence
acid sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020562602A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523140A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030946 external-priority patent/WO2019217332A1/en
Publication of JP2021523140A publication Critical patent/JP2021523140A/ja
Publication of JP2021523140A5 publication Critical patent/JP2021523140A5/ja
Withdrawn legal-status Critical Current

Links

JP2020562602A 2018-05-07 2019-05-06 Nkg2d、cd16、及び腫瘍関連抗原に結合するタンパク質 Withdrawn JP2021523140A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862667844P 2018-05-07 2018-05-07
US62/667,844 2018-05-07
PCT/US2019/030946 WO2019217332A1 (en) 2018-05-07 2019-05-06 A protein binding nkg2d, cd16 and a tumor-associated antigen

Publications (2)

Publication Number Publication Date
JP2021523140A JP2021523140A (ja) 2021-09-02
JP2021523140A5 true JP2021523140A5 (cg-RX-API-DMAC7.html) 2022-05-13

Family

ID=68468469

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020562602A Withdrawn JP2021523140A (ja) 2018-05-07 2019-05-06 Nkg2d、cd16、及び腫瘍関連抗原に結合するタンパク質

Country Status (6)

Country Link
US (1) US20210238290A1 (cg-RX-API-DMAC7.html)
EP (1) EP3790585A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021523140A (cg-RX-API-DMAC7.html)
KR (1) KR20210018275A (cg-RX-API-DMAC7.html)
CN (1) CN112437672A (cg-RX-API-DMAC7.html)
WO (1) WO2019217332A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2014198748A1 (en) * 2013-06-11 2014-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
DE102013019352A1 (de) * 2013-11-13 2015-09-17 Elke Pogge Von Strandmann Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort
EP4050026A1 (en) * 2014-04-01 2022-08-31 Adimab, LLC Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody
MX2016017393A (es) * 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
WO2016122701A1 (en) * 2015-01-26 2016-08-04 Macrogenics, Inc. Anti-dr5 antibodies and molecules comprising dr5-binding domains thereof
JP6840682B2 (ja) * 2015-06-23 2021-03-10 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. 多重特異的抗原結合タンパク質
WO2017177337A1 (en) * 2016-04-15 2017-10-19 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
US20230002450A1 (en) * 2019-02-18 2023-01-05 Courier Therapeutics, Inc. Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner

Similar Documents

Publication Publication Date Title
JP2020510653A5 (ja) Ceaを標的にする多重特異性結合タンパク質
JP2020521448A5 (cg-RX-API-DMAC7.html)
JP2021098733A5 (cg-RX-API-DMAC7.html)
JP2020508997A5 (cg-RX-API-DMAC7.html)
JP2023106433A5 (cg-RX-API-DMAC7.html)
JP2020533311A5 (ja) NKG2D、CD16およびNectin4に結合するタンパク質
JP2020522474A5 (cg-RX-API-DMAC7.html)
JP2021534096A5 (cg-RX-API-DMAC7.html)
JP2020522473A5 (cg-RX-API-DMAC7.html)
JP2021035388A5 (ja) Caix、ano1、メソテリン、trop2またはクローディン−18.2を標的にする多重特異性結合タンパク質
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2021098732A5 (cg-RX-API-DMAC7.html)
JP2023052214A5 (cg-RX-API-DMAC7.html)
FI3582806T3 (fi) Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja
JP2021523913A5 (cg-RX-API-DMAC7.html)
RU2021110369A (ru) Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
JP2021512630A5 (cg-RX-API-DMAC7.html)
JP2019536430A5 (cg-RX-API-DMAC7.html)
JP2022551969A5 (cg-RX-API-DMAC7.html)
JP2020510646A5 (cg-RX-API-DMAC7.html)
JP2021533169A5 (cg-RX-API-DMAC7.html)
JP2023509448A5 (cg-RX-API-DMAC7.html)
RU2019128134A (ru) Антитело против gprc5d и молекула, содержащая антитело
JP2020507577A5 (cg-RX-API-DMAC7.html)
RU2019129511A (ru) Белки, связывающие gd2, nkg2d и cd16